Although cigarette smoking is the dominant risk factor for several epithelial cancers, only a small fraction of individuals with tobacco exposure develop cancer. The underlying hypothesis is that genetic factors may render certain smokers more susceptible to cancer than others. Genetic alterations in critical regulatory pathways may predispose cells to carcinogenesis. These pathways include regulation of xenobiotic metabolism; control of genomic stability, including DNA repair mechanisms, cell-cycle checkpoints, apoptosis and telomere length; and control of microenvironmental factors, such as matrix metalloproteinases, inflammation and growth factors. In addition, epigenetic events, such as promoter hypermethylation and loss of imprinting, are also involved in carcinogenesis. In this review, we will summarize recent advances in genetic susceptibility to tobacco-related cancer. Emphasizing on risk assessment, we will describe how genetic variations in the above-mentioned genetic pathways modify the tobacco-related cancer risk. In addition, we will discuss how genetic variations may assist in predicting clinical outcome, such as the natural history of cancer and treatment response. The measurements of genetic susceptibility by both genotypic and phenotypic assays are covered in the text. Finally, we present a number of current concerns that need to be addressed as the exciting field of molecular cancer epidemiology advances rapidly.
Introduction
Cigarette smoking is the dominant risk factor for several epithelial cancers, including the lung, oral cavity, pharynx, larynx, esophagus, pancreas, cervix, kidney, and bladder. Specifically, tumorigenesis in tobaccorelated cancers is influenced by the interaction of genetic susceptibility and exposure to cigarette smoking. The strongest evidence exists for the relationship between tobacco and lung cancer, as 87% of lung cancers are attributed to tobacco exposure, and the relative risk for lung cancer in current smokers is up to 20 times higher than that for those who have never smoked (Shopland et al., 1991) . However, not all smokers develop cancer. Peto et al. (2000) estimated that the cumulative risk of death from lung cancer by age 75 years (in the absence of other causes of death) was 16% in 1990 in male cigarette smokers and 10% in female cigarette smokers. Given that tobacco-related cancers develop in only a small fraction of the individuals exposed to tobacco smoke, it is tempting to hypothesize that genetic factors may render some smokers more susceptible to cancer. The cardinal feature by which inherited predisposition is recognized clinically is family history. Genetic predisposition to bladder cancer was evident in a comprehensive review of familial bladder cancer (Kiemeney and Schoenberg, 1996) , and a significant familial component in lung cancer was indicated using segregation analysis (Sellers et al., 1994) . Gene-environment interactions have been associated with numerous tobacco-related cancer risks (Shields and Harris, 2000) . Until recently, classic epidemiologic approaches have utilized a black box approach to sort out cancer risks, which often limited the evaluation of host susceptibility factors to age, sex, and ethnicity in studying exposure-cancer associations, and failed to identify potential geneenvironment interactions in cancer causation. Molecular epidemiology integrates advances in molecular biology and cancer genetics to explore carcinogenetic mechanisms, to identify susceptible subgroups, and to increase the accuracy of exposure estimation and disease outcome prediction.
Multiple carcinogens have been found in cigarette smoke, with polycyclic aromatic hydrocarbons (PAHs), N-nitrosamines, aromatic amines, heterocyclic aromatic amines, and aldehydes forming the major classes of carcinogens (Hecht, 1999) . In all, 69 carcinogens in cigarette smoke have been identified that induce lung tumors in animals or humans (Hoffmann et al., 2001) . Metabolic activation of these carcinogens leads to DNA adduct formation, whereby the active metabolite binds covalently to DNA. DNA repair systems will repair many DNA adducts; however, those that are not repaired can lead to miscoding. Multiple mutations can lead to loss of normal controls on cell growth. In cases where the damage is excessive and cannot be repaired, the cells will go into programmed cell death, that is, apoptosis. Therefore, genetic alterations in critical regulatory pathways may predispose to carcinogenesis. These pathways include: regulation of xenobiotic metabolism; control of genomic stability, including DNA repair mechanisms, cell-cycle checkpoints, apoptosis, and telomere length; and control of microenvironment, such as matrix metalloproteinases (MMPs), inflammation, and growth factors. In addition to these genetic events, epigenetic events, including promoter hypermethylation and loss of imprinting, are also actively involved in carcinogenesis.
This review will summarize recent advances in the identification of genetic susceptibility factors to tobaccorelated cancers in risk assessment as well as clinical outcome prediction. In the next section, we will discuss how the genetic variations in xenobiotic metabolism, DNA repair, cell-cycle controls, apoptosis, telomere length, MMPs, inflammation factors, hormones and growth factors, and epigenetic events modify the tobacco-related cancer risk. In the section on outcome prediction, we will discuss how the genetic variations predict the treatment response and natural history of cancer. The measurement of genetic susceptibility by both genotypic and phenotypic assays will be illustrated in the text.
Genetic variations in cancer risk assessment

Carcinogen metabolism
The details of metabolic activation, adduct formation, and detoxification of tobacco carcinogens have been extensively studied. Phase I enzymes typically are involved in the activation of carcinogenic substrates to ultimate carcinogens. The cytochrome P450 family of Phase I enzymes, encoded by the CYP family of genes, is involved in the initial oxygenation of the carcinogenic substrate. Some of the metabolites produced by this reaction react with DNA to form covalent adducts. For example, benzo(a)pyrene, a polyaromatic hydrocarbon, is converted to 7,8-diol-9,10-epoxides (BPDE), which is one of the four enantiomers forming DNA adducts. Similar activation of one of the N-nitrosamines, 4-methylnitrosamino-1-3-pyridyl-1-butanone (NNK), by the P450 system produces metabolites that form methyl and pyridyloxobutyl DNA adducts. Detoxification of the toxic metabolites occurs via the action of multiple Phase II enzymes, most notably the glutathione-Stransferases. The balance between activation and detoxification is believed to affect cancer development.
Genetic variability in these pathways has been of particular interest in studies of tobacco-related cancer risk. Polymorphisms in Phase I and II enzymes that are involved in the activation and detoxification of carcinogens have been identified and may be associated with differential ability to process carcinogens. Accumulation of active carcinogen metabolites and hence increased DNA adduct formation is hypothesized to increase tobacco-related cancer risk. The polymorphisms in the CYP superfamily of genes may produce extinguished, reduced, altered, or increased enzyme activity affecting the activation and detoxification of carcinogens. Thus, epidemiologic studies have demonstrated that the variant CYP genotypes may alter susceptibility to tobacco-related cancer. Studies in the lung tissue of cancer-free autopsy cases have demonstrated that polymorphisms in CYP2D6, CYP2E1, and GSTM1 are associated with higher DNA adduct levels, suggesting that variations in metabolic pathways can play a role in how individuals respond to carcinogen exposure (Kato et al., 1995) . A list of metabolic enzymes and their relative genetic polymorphisms is summarized in Table 1 . Numerous studies have extended this line of analysis to Genetic susceptibility to tobacco-related cancer X Wu et al investigate whether this differential ability to metabolize carcinogens leads to differential tobacco-related cancer risk. Overall, the data from studies of these polymorphisms have generated inconsistent results. These inconsistencies may be due to either small sample sizes or the varied frequencies of the polymorphic alleles within different ethnic populations. CYP1A1: CYP1A1 is a member of the cytochrome P450 family, a class of Phase I enzymes. It is hypothesized that interindividual variations in the ability to activate carcinogens such as polyaromatic hydrocarbons may lead to differential carcinogenic effect. At least two variant polymorphisms have been described in the CYP1A1 gene. The first is a T 3801 C base change in intron 6, which results in a new MspI restriction site, the second is an A 2455 G base change in exon 7, which results in an Ile to Val amino-acid change (Kawajiri et al., 1990; Hayashi et al., 1991) . These polymorphisms appear to be linked. Consistency in study results is lacking, with widely disparate results among different populations.
In Japanese populations, both of the CYP1A1 variant polymorphisms have been associated with increased lung cancer risk. Nakachi et al. (1991) were the first to report an association of the MspI polymorphism with lung cancer risk. Patients with lung cancer had a more than twofold higher frequency of having the homozygous variant genotype. Among patients with squamous cell carcinoma, the homozygous variant genotype was associated with increased risk of developing lung cancer, especially at a lower cumulative dose of cigarette smoke. At low levels of exposure to cigarette smoke, the odds ratio for developing lung cancer among those with the homozygous variant genotype was 7.31 (95% CI: 2.13-25.12). This increased risk was persistent, but of lesser magnitude, at higher dose levels of cigarette smoke. Okada et al. (1994) reported similar findings. The Ile462Val polymorphism of CYP1A1 has also been associated with lung cancer risk in Japanese populations. Again, the homozygous variant Val-Val genotype was associated with lung cancer at lower cumulative doses of cigarette smoke (Nakachi et al., 1993) . One explanation posited for the relationship with low dose level has been that at high dose levels, the relevant enzyme is saturated, while at low doses it is not. The effects of genetic variability and differential enzymatic activity are more apparent at the lower cigarette dose levels, when saturation has not yet been reached.
Outside of Japan, the results have been less consistent. Individual studies may be underpowered, since the CYP1A1 polymorphisms, which are relatively common in Japan (30% of population), are much less common in Europeans and North Americans (o10% of population) (Warren and Shields, 1997) . While a study of African-Americans and Mexican-Americans showed a twofold increased risk of lung cancer among light smokers with the MspI variant genotype (Ishibe et al., 1997) , a Brazilian study showed increased risk with the Ile-Val polymorphism and not the MspI polymorphism (Hamada et al., 1995) . Reports from Norway and Finland show a lack of association of either of the CYP1A1 polymorphisms with lung cancer risk (Tefre et al., 1991; Hirvonen et al., 1992) . A meta-analysis provided little support for the association of CYP1A1 polymorphisms with lung cancer risk (Houlston, 2000) . Given the small sample sizes in these studies, Vineis Vineis et al. (2003) conducted a pooled analysis using the international Gene Susceptibility to Environmental Carcinogenesis (GSEC) data set. These data set included raw data from 22 case-control studies, with a total of 2451 cases and 3358 controls; this comprised approximately half of the case control studies published at that time. An association was found in Caucasians between the CYP1A1 homozygous MspI variant and lung cancer risk, when adjusted for age and gender (OR ¼ 2.36, 95% CI: 1.16-4.81); the association held for both squamous cell carcinoma and adenocarcinoma. Interestingly, among Asians in this pooled analysis, this association failed to meet statistical significance; of note, studies such as the Nakachi study were not included, making the Asian data difficult to interpret. summarized the association between CYP1A1 polymorphisms and head and neck cancer, esophageal cancer, and lung cancer. There was over-representation of the CYP1A1 Ile-Val variant among Caucasian patients with oral cancer, but the prevalence of the Ile-Val variant was significantly higher in nonsmokers than smokers, although the number of nonsmokers was low (Park et al., 1997) . Similarly, an increased prevalence of CYP1A1 Val-Val variant was found among Japanese patients with head and neck cancers and especially those with pharyngeal cancer. Individuals with the homozygous CYP1A1 MspI (m1/ m1) variant were at significantly increased risk for oral squamous cell carcinoma, in particular, after exposure to low concentrations of PAH (Morita et al., 1999) . The combination of homozygous CYP1A1 MspI (m1/m1) variant and GSTM1 0/0 further increased the risk. Studies in Caucasians and Japanese showed no association with esophageal cancer. Esophageal cancer patients in China who were heavy smokers had a threefold higher frequency of the CYP1A1 Val-Val variant. The risk was further increased in patients with the combination of CYP1A1 Val-Val and GSTM1 0/0 genotypes (Nimura et al., 1997) . In bladder cancer, two studies of Japanese and Caucasians showed no significant associations (Katoh et al., 1995; Brockmo¨ller et al., 1996) .
CYP2E1: The shift in histology from squamous cell to adenocarcinoma has been attributed to changes in cigarette content and smoking behavior. Filtered low tar cigarettes that became common after the 1950s permit deeper inhalation of smoke to compensate for the lesser nicotine content; as particulate matter deposits further along the bronchial tree, peripherally located adenocarcinomas become more common. In addition, the newer cigarettes contain less PAHs and more nitrosamines than older cigarettes. CYP2E1 is a member of the CYP Phase I family that is involved in the activation of nitrosamines. Le Marchand et al. (1998) performed a population-based case-control study among 341 lung cancer cases and 456 controls, and found that CYP2E1 polymorphisms were associated with a decrease in adenocarcinoma risk. Wu et al. (1997 Wu et al. ( , 1998a found that CYP2E1 polymorphism was associated with increased risk of lung cancer in African American and Mexican American. On the other hand, the presence of at least one variant CYP1A1 MspI allele was associated with an increased risk of squamous cell carcinoma, both alone (2.4-fold increase in risk) and in combination with GSTM1 deletion (3.1-fold increase in risk). The authors suggest that the associations between CYP1A1 and squamous cell carcinoma and CYP2E1 and adenocarcinoma may indicate a specificity of PAHs for inducing squamous cell carcinoma and NNKs for inducing adenocarcinoma. Several studies showed no association between head and neck cancer and CYP2E1 variants ; however, Chinese patients who were not betel quid chewers had a higher prevalence of the variant allele (Hung et al., 1997) . The variant allele was over-represented among Chinese esophageal cancer patients (Lin et al., 1998) . In bladder cancer, several studies found no association with bladder cancer (Anwar et al., 1996; Brockmo¨ller et al., 1996; Farker et al., 1998) .
CYP2A13: CYP2A13 is expressed primarily in the respiratory tract and participates in the metabolic activation of N-nitrosamines such as NNK. A polymorphism in CYP2A13 has been identified where a C-T transition leads to an Arg-Cys substitution at position 257. The variant 257Cys protein has a 2-3-fold reduced capacity to activate NNK compared to the 257Arg protein (Su et al., 2000; Zhang et al., 2002) . In a study of 724 lung cancer patients and 791 controls, Wang et al. (2003a) demonstrated that the variant CYP2A13 genotype (CT or TT) was associated with reduced risk for lung cancer, particularly adenocarcinoma (OR ¼ 0.41, 95% CI: 0.23-0.71). The reduction in risk did not reach statistical significance for squamous cell or other histolologies. The reduced risk for adenocarcinoma was apparent only in smokers, and in light smokers rather than heavy smokers, again suggesting that genetic polymorphisms may play a greater role when the carcinogen dose is present, but does not saturate, enzymatic capacity.
GSTM1: The glutathione-S-transferases are a class of Phase II enzymes that protect DNA against damage and adduct formation by conjugating glutathiones to electrophilic substances, creating a hydrophilic less reactive metabolite that can be excreted. Different GST families exist (alpha, mu, pi, theta) (Hayes and Pulford, 1995) . Large variations in enzymatic activity have been noted for several GSTs. About 50% of the population is homozygous for a deletion in the GSTM1 gene that leads to null expression (Seidegard et al., 1988) . Since the GSTM1 enzyme is thought to be important in detoxifying carcinogens, numerous studies have investigated the possible association of the GSTM1 null genotype with lung cancer risk.
Several studies have found an association between the GSTM1 null mutation and lung cancer across many populations. In a Japanese population, the GSTM1 null genotype was positively correlated with squamous cell carcinoma of the lung, although not with adenocarcinoma (Kihara et al., 1993) . Similar analysis in a Finnish population again demonstrated a correlation of the GSTM1 null genotype with squamous cell cancer, as well as in Scottish, Norwegian, and Turkish populations (Zhong et al., 1991; Hirvonen et al., 1993; Ryberg et al., 1997; Pinabasi et al., 2003) . However, data are not consistent and some studies have shown a lack of significant association between the GSTM1 null genotype and lung cancer risk for both squamous cell carcinoma and overall lung cancer (London et al., 1995; Rebbeck, 1997) . A meta-analysis of 12 casecontrol studies comprising 1593 cases and 2135 controls showed a moderate increase in risk of lung cancer across all histologies with the GSTM1 null genotype, with an odds ratio of 1.41 (95% CI: 1.23-1.61) (McWilliams et al., 1995) . A more recent meta-analysis of 43 studies including over 18 000 individuals shows a smaller, although still statistically significant, OR of 1.17 (95% CI: 1.07-1.27) (Benhamou et al., 2002) . In bladder cancer, the null genotype of GSTM1 is consistently associated with increased risk of bladder cancer. In a recent meta-analysis (including 17 studies, 2149 cases, 3646 controls), GSTM1 null status was associated with increased risk of bladder cancer with an odds ratio of 1.44 (95% CI: 1.23, 1.68) (Engel et al., 2002) . In a review of 24 published papers on squamous cell carcinoma of the head and neck, the results of these studies are inconsistent, with some reporting weak-to-moderate associations and others finding no elevation in risk for the main effect of the gene (Geisler and Olshan, 2001) . Several studies in Asia reported the positive association between GSTM1 polymorphism and esophageal cancer (Nimura et al., 1997; Gao et al., 2002; Wang et al., 2004) .
The combination of the CYP1A1 and GSTM1 variant genotypes has been of particular interest, since the combined Phase I and II actions of increased activation and decreased metabolism of PAH in tobacco smoke have been hypothesized to lead to increased lung cancer risk. Numerous studies have explored this association; perhaps the strongest studies come from Japan, although limited in general by small sample size. The combined genotype of the CYP1A1 variant genotype and the GSTM1 null genotype was shown to enhance the risk of smoking-related lung cancers in a Japanese population. This was demonstrated with the Ile-Val polymorphism by Hayashi et al. (1992) , who showed an increased frequency of the homozygous Val-Val genotype combined with the GSTM1 null genotype in lung cancer patients compared to controls (8.5 vs 2.2%). Nakachi et al. (1993) reported similar results with both the MspI and Ile-Val polymorphisms and GSTM1 null. In a case-control study, they found either of the two CYP1A1 susceptible genotypes combined synergistically with the deficient GSTM1 genotype to create a high risk for lung cancer (OR 16 and 41, respectively, , respectively) at low cigarette dose levels. Of those who developed lung cancer in the low cigarette dose group, 87% had at least one of the three homozygous variant genotypes. The authors suggest that, particularly when cigarette dose is low, CYP1A1 and GSTM1 may play important roles in defining susceptibility to lung cancer. The synergistic effect was again demonstrated by Kihara et al. (1994) : individuals with the variant genotypes in both CYP1A1 and GSTM1 had a much higher risk of lung cancer than those with the variant CYP1A1, but wild-type GSTM1 (OR of 21.9 versus 3.2). Studies in Scandinavian populations as well as American populations support the finding of increased risk of lung cancer with the combination of variant CYP1A1 and GSTM1 genotypes (Alexandrie et al., 1994; Anttila et al., 1994; GarciaClosas et al., 1997) . A pooled analysis of 302 cases and 1631 controls among Caucasian nonsmokers showed an increased risk with the combined CYP1A1 Ile/Val polymorphism and GSTM1 null polymorphism (Hung et al., 2003) .
GSTP1: GST pi is a member of the GST family of Phase II enzymes that has high expression in the lung. Polymorphisms in GSTP1 have been reported, where an A-G base change leads to an isoleucine-valine substitution resulting in lower enzymatic activity and higher levels of PAH-DNA adducts (Watson et al., 1998) . Several studies showed no statistically significant association between GSTP1 polymorphisms and lung cancer risk (Harris et al., 1998; Katoh et al., 1999; ToFigueras et al., 1999; Nazar-Stewart et al., 2003) . However, the largest study with a sample of 1042 cases and 1161 controls found that the GSTP1 homozygous variant genotype was associated with higher lung cancer risk at any level of smoking exposure when compared to wild type, approximately doubled the risk associated with pack-years of smoking (Miller et al., 2003b) . The same group analysed the GSTP1 variant genotype in relation to environmental tobacco smoke exposure and lung cancer risk. Environmental tobacco smoke exposure was associated with higher lung cancer risk, and the presence of the homozygous variant (GG) genotype increased this risk even further (Miller et al., 2003a) . Most of studies in other tobacco-related cancers do not observe the significant association. The combination of GSTM1 null and GSTP1 GG genotypes may confer increased lung cancer risk (Ryberg et al., 1997; Kihara and Noda, 1999; Perera et al., 2002) . In a study of 1694 cases and controls, double variants in GSTM1 and GSTP1 as well as GSTP1 and p53 have been associated with increased lung cancer risk among individuals aged 55 years or younger .
GSTT1: GSTT1, another member of the GST family of Phase II enzymes, is involved in the metabolism of monohalomethanes and ethylene oxide found in tobacco smoke. Results have not supported an association with lung cancer risk (To-Figueras et al., 1997; Malats et al., 2000; Stucker et al., 2002; Ruano-Ravina et al., 2003; Wang et al., 2003b) . In bladder cancer, the association is not consistent (Abdel-Rahman et al., 1998) .
NAT2: N-acetyltransferase 2 (NAT2) has dual actions; it inactivates aromatic amines through N-acetylation, but can also activate certain arylamine metabolites through N-and O-acetylation. There are several widely studied polymorphisms for the NAT2 gene associated with decreased activity or stability of the enzyme.
Phenotypically these polymorphisms result in slow or fast acetylation. Studies have been conflicting with regard to the association with lung cancer risk. Most studies report no overall increase in risk with either the slow or fast acetylators (Philip et al., 1988; Martinez et al., 1995; Bouchardy et al., 1998; Saarikoski et al., 2000) , whereas a few have reported increased risk with either the slow (Oyama et al., 1997; Seow et al., 1999) or fast acetylator genotype. In the largest study of 1115 lung cancer patients and 1250 controls, no association was found between the NAT2 genotype and lung cancer risk (Zhou et al., 2002b) . However, a significant interaction was found with smoking: among nonsmokers, the rapid acetylator genotype had a decreased lung cancer risk when compared to the slow acetylator genotype; among smokers this relationship reversed; and the rapid acetylators had a higher risk. The authors hypothesize that for nonsmokers, NAT2 may provide an alternative pathway to CYP-mediated activation, providing a means of N-acetylating and detoxifying the aromatic amines and protecting against cancer. However, in smokers, CYP oxidation is markedly induced by cigarette smoke, and the production of reactive intermediates is increased. In this setting NAT2 may instead O-acetylate these metabolites and thereby produce more reactive metabolites, thus augmenting cancer risk. In bladder cancer, the association between NAT2 polymorphisms and bladder cancer risk is quite consistent, with slow acetylators having modestly increased risk (d'Errico et al., 1996; Johns and Houlston, 2000; Marcus et al., 2000a, b) . In a meta-analysis including data from 21 published case-control studies, the pooled odds ratio of bladder cancer associated with slow acetylator status was 1.31 (95% CI: 1.11-1.55). There is also evidence for a multiplicative interaction between smoking and NAT2 (Marcus et al., 2000a) . mEH: Microsomal epoxide hydrolase has several functions and like NAT2 can act as both an activator and detoxifier of carcinogens. In its detoxifying role, mEH catalyses the hydrolysis of highly reactive epoxide intermediates to less reactive dihydrodiols that are excretable. In its activating role, mEH can metabolize polyaromatic hydrocarbons into reactive diolepoxides. Several polymorphisms have been identified, including a T-C base change in exon 3 leading to a tyrosinehistidine substitution at residue 113, which is associated with decreased activity of the enzyme, and a A-G base change in exon 4 leading to a histidine-arginine substitution at residue 139, which leads to increased enzymatic activity (Hassett et al., 1994) .
Several studies have noted an increased risk of lung cancer among those carrying the polymorphisms associated with increased enzymatic activity. A study of Mexican-Americans and African-Americans found a greater risk of lung cancer among young MexicanAmericans with the exon 4 polymorphism, but not the exon 3 polymorphism. No association was observed for African-Americans . The homozygous variant genotype at exon 4, conferring increased enzymatic activity, was again found to be associated with increased lung cancer risk in two studies in Texas. The combination of exon 3 and 4 polymorphisms that confer high enzymatic activity also significantly increased risk Cajas-Salazar et al., 2003) . In a Taiwanese population, high mEH activity, as defined by the corresponding combination of exon 3 and 4 polymorphisms, was associated with risk for squamous cell carcinoma , and in a French population . High mEH activity was similarly associated with lung cancer risk. Interestingly, a study of 974 Caucasian lung cancer patients and 1142 controls found no relationship between mEH polymorphisms and lung cancer risk overall. However, there was evidence of gene-environment interaction, as having the low activity mEH genotypes was a risk factor for lung cancer among nonsmokers (OR 1.89 95% CI: 1.08-3.28), but protective among heavy smokers (OR 0.65 95% CI: 0.42-1.00) . This effect was stronger in squamous cell than adenocarcinoma. The authors hypothesize that this difference may be explained by the dual actions of mEH. In nonsmokers, having low mEH activity may lead to decreased ability to detoxify environmental pollutants, thus increasing lung cancer risk. In smokers, the PAH of cigarette smoke may be activated by mEH; hence, having low activity is protective.
NQO1: NAD(P)H quinone oxidoreductase 1, formerly referred to as DT-diaphorase, is a cytosolic enzyme catalysing the two-electron reduction of quinone substrates. NQO1 either metabolically activates or detoxifies carcinogens present in cigarette smoke. Benzo(a)pyrene is one of the most important carcinogens and the formation of benzo(a)pyrene quinone-DNA adduct is prevented by NQO1 (Joseph and Jaiswal, 1994) . In contrast, carcinogenic heterocyclic amines present in smoke are metabolically activated by NQO1. Therefore, this enzyme is thought to be involved in both metabolic activation and detoxification of carcinogenic agents that could be involved in tobaccorelated carcinogenesis. The NQO1 gene is located on chromosome 16q22. Recently, a polymorphism of the gene encoding NQO1 has been described. The polymorphic variant of the gene (a C to T transition at base pair 609, codon 187) is associated with reduced NQO1 activity (Ross et al., 1996; Siegel et al., 1999) . The three genotypes of this gene are the homozygous wild-type C/ C (normal activity), the heterozygous C/T genotype (mild activity), and the homozygous rare allele T/T genotype (2-4% of normal activity).
There have been several studies examining the relationship between the NOQ1 polymorphism and lung cancer risk, but the conclusions have been contradictory. Rosvold et al. (1995) reported that the rare allele was observed to be approximately twice as common in Caucasian cases as in controls. Lewis et al. (2001) also reported that the variant allele was associated with a non-ignificant increased risk of lung cancer and a significant increased risk (OR ¼ 3.80, 95% CI: 1.19-12.1) of small-cell lung cancer. They concluded that the variant NQO1 allele may play in activating genotoxins. In contrast, some studies have shown that the allele is inversely associated with lung cancer risk Lin et al., 1999) . Recently, a large study showed that no difference for the genotype distribution between lung cancer cases and controls . However, there was a gene-environment interaction between the genotype and smoking. Although only a few studied in bladder cancer, a positive association was evident Park et al., 2003) . Park et al. (2003) reported that the variant genotypes of NQO1 were associated with a higher risk of bladder cancer in Caucasians (OR ¼ 1.51; 95% CI: 1.01-2.25).
Myeloperoxidase (MPO): Following immunological and/or chemical insults, neutrophils release MPO and undergo a respiratory burst, which is characterized by a massive increase in oxygen consumption and a consequent NADPH-dependent production of superoxide and other free radicals. MPO is present in the primary granules of neutrophils and catalyses the production of the potent bacteriotoxic oxidizing agent hypochlorous acid (a one-and two-electron oxidant that can attack endogenous molecules including DNA) from hydroxyl radicals and chloride ions. A significant proportion (25-40%) of the hydrogen peroxide formed by activated neutrophils may be converted to hypochlorous acids. MPO metabolically activates a wide range of tobacco smoke mutagens and environmental pollutants to DNAdamaging metabolites, including aromatic amines, the promutagenic derivatives of PAHs and heterocyclic amines (Petruska et al., 1992; Williams et al., 1998) . The MPO gene is located on chromosome 17. A G to A transition at position À463 in the promoter region of the MPO gene, which leads to the loss of a SP1 transcription factor-binding site in an Alu hormone-responsive element, has been shown to reduce MPO mRNA expression (Austin et al., 1993) . Although several studies found significant associations between MPO genotype and lung cancer risk, estimates of the nature and extent of the association varied considerably between studies. For example, possession of the A/A genotype (8-10% of the population) was associated with a decreased risk of lung cancer in Caucasians (OR ¼ 0.30, 95% CI: 0.10-0.93) and 39% reduction (not statistically significant) in African-Americans compared with those with two G alleles (London et al., 1997) . A second study of populations with Caucasians, Japanese or Hawaiian ethnicity reported an overall 50% reduction in risk (95% CI: 0.2-1.3) for those with the A/A genotype compared with those with the G/G genotype (Le Marchand et al., 2000) . In a case-control study in the Berlin area, possession of one or two A alleles was suggested as being a protective factor for cancer of the lung (OR ¼ 0.58, 95% CI: 0.38-0.88) and larynx (OR ¼ 0.63, 95% CI: 0.43-0.92), but not for cancer of the pharynx (OR ¼ 0.82, 95% CI: 0.57-1.17) (Cascorbi et al., 2000) . Two studies in Caucasian also has reported an overall reduction in risk for those possessing the variant allele (Schabath et al., 2000 (Schabath et al., , 2002 .
Others: Many other enzymes involved in the metabolism of carcinogens have been studied. Examples include manganese superoxide dismutase, which detoxifies oxygen radicals by catalysing the conversion of superoxide radicals into hydrogen peroxide and oxygen. An alanine to valine substitution at codon 16 has been identified that may be associated with less efficient enzyme transport into mitochondria. The Val/Val genotype has been associated with increased risk of lung cancer as compared to wild type (OR ¼ 1.67, 95% CI: 1.27-2.20), as was the heterozygous variant genotype (OR ¼ 1.34, 95% CI: 1.05-1.70) . SULT1A1 enzyme is a member of the sulfotransferase family that alters biological activities of numerous carcinogenic and mutagenic compounds through sulfation. A genetic polymorphism in the coding region of SULT1A1 gene has been associated with modulated enzyme activity. There is a G-A nucleotide polymorphism in SULT1A1 gene that codes for an Arg-His substitution, which results in decreased activity and thermal stability of the SULT1A1 enzyme. Wang et al. (2002b) reported that there was the variant allele of SULT1A1 was associated with increased lung cancer risk with adjusted OR of 1.41 (95% CI: 1.04-1.91).
DNA damage and repair
The human genome has three billion base pairs that encode over 30 000 genes. The stability of human genome must be under continuous surveillance because the integrity of the DNA molecule is constantly under attack by both endogenous and exogenous sources, such as reactive products of cellular metabolism, environmental mutagens, ionizing radiation, and therapeutic drugs. The maintenance of genomic integrity is mainly accomplished by DNA repair systems. The importance of functional DNA repair system is best appreciated by the direct link of several human diseases to defects in DNA repair machinery. These human repair deficiency diseases, which are often characterized by the accumulation of mutations in the genome and increased cancer incidence, include xeroderma pigmentosum (XP), ataxia telangiectasia (AT), Bloom's syndrome, and hereditary nonpolypopsis colorectal cancer (HNPCC). The sheer number of genes in human genome that are devoted to DNA repair pathways is another testament of the importance of DNA repair. Wood et al. (2001) compiled a comprehensive list of DNA repair genes based on the draft of human genome sequence and identified about 130 human DNA repair genes. The products of these genes are mainly involved in four major DNA repair pathways in human cells: mismatch repair, nucleotide excision repair (NER), base excision repair (BER), and double strand break (DSB) repair. Each of these four pathways repairs distinct types of DNA damages and calls for specialized protein complexes, which can detect damage, interrupt cell division, and repair DNA lesions (Christmann et al., 2003) . As tobacco smoke contains an assortment of carcinogens with differing chemical structures and may cause a variety of DNA damages, which therefore require distinct repair pathways, genes of the above-mentioned pathways, in particular, NER, BER, and DSB repair pathways, may play important roles in the initiation of tobacco-related cancer. NER mainly removes bulky DNA adducts, which are typically generated from exposure to environmental genotoxic agents such as ultraviolet (UV) and BPDE. BER pathway is responsible for oxidized DNA bases, which may arise spontaneously within the cell, during inflammatory responses, or from exogenous agents. DSB is responsible to repair double-strand break caused by a plethora of pathological stimulus, including ionizing radiation, chemotherapeutic drugs, free radicals, and telomere dysfunction. There are two distinct and complementary pathways for DSB repair, that is,, homologous recombination (HR) and nonhomologous end-joining.
Polymorphisms in DNA repair genes DNA repair capacity (DRC) is substantially varied within human population. Defects in DRC may lead to genetic instability and carcinogenesis. A growing number of literature has suggested that common polymorphisms in DNA repair genes may alter protein function and contribute to the interindividual differences in DRC and, therefore, may modulate cancer risks. These studied DNA repair genes include XPD, XPA, XPC, XPG, XRCC1, HOGG1, APEX, XRCC3, etc. We summarize the common nonsynonymous single-nucleotide polymorphisms (nsSNPs) (variant allele frequency X0.02) in genes involved in three different DNA repair pathways, including NER, BER, and DSB repair in Table 2 .
NER genes: All key NER factors have been cloned and the core of the 'cut-and-paste' reaction has been reconstituted in vitro from purified components (de Laat et al., 1999) . Most of the NER genes are polymorphic (Table 2) . Besides the nsSNPs presented in Table 2 , polymorphisms in other regions have also been studied in several NER genes, such as, a polymorphism in 5 0 untranslated region in XPA gene, a poly-AT insertion in intron 9 of XPC gene, etc.
ERCC2 (or XPD) is a major component of the general transcription factor complex TFIIH, which mediates strand separation at the site of the DNA lesion. Of particular interest are two nsSNPs, Asp312Asn and Lys751Gln. Spitz et al. found that neither Gln751 nor Asn312 variant alleles of XPD gene were associated with lung cancer risk. However, for those homozygous for the variant genotype at both locus, the adjusted risk estimate was 1.84 (95% CI: 1.11-3.04; P ¼ 0.018 for trend) . They also found that both Gln751 and Asn312 variant alleles were associated with decreased DRC in lung cancer patients. In a large lung cancer study (1092 cases, 1240 controls), Zhou et al. (2002a) found that the Asn312Asn genotype was associated with increased lung cancer risk (OR ¼ 1.47, 95% CI: 1.1-2.0; Asn/Asn versus Asp/ Asp). However, while the variant Asn allele was a risk factor among nonsmokers and light smokers, it was a protective factor among heavy smokers. The authors hypothesize that among light smokers or nonsmokers, DNA damage induced by tobacco-related carcinogens may be differentially repaired by polymorphic variants of the ERCC2 gene. The same study did not find a significant association between the Lys751Gln polymorphism and lung cancer risk. In a few other studies, the association was reversed. For example, Lunn et al. (2000) found the Asp312Asn polymorphism did not affect DNA repair, but that the Lys751Lys wild-type genotype led to more chromatid aberrations. Butkiewicz et al. 92001) studied 96 cases and 96 controls in Poland and found an increased risk of lung cancer with the Asp312Asp genotype, which suggested that the variant Asn allele was protective, however, the sample size was very small.
Other NER genes examined in epidemiological studies were XPA, XPC, and XPG. XPA recognizes the damage in an open DNA conformation and is crucial in the assembly of the remainder of the repair machinery. Wu et al. studied a XPA polymorphism in the 5 0 noncoding region of XPA and found that the presence of one or two copies of the G allele was associated with a reduced lung cancer risk for Caucasians, Mexican-Americans, and African-Americans (Wu et al., 2003b) . In addition, control subjects with one or two copies of the G allele showed more efficient DRC than did those with the homozygous A allele. These data suggest that this XPA SNP modulates NER capacity and lung cancer risk. The association was confirmed by another lung cancer study in Korean population (Park et al., 2002b) . XPC has been identified as a DNAdamage sensor and repair recruitment factor. Shen et al. (2001b) reported that the poly-AT insertion in intron 9 of XPC gene was associated with an elevated risk of HNSCC. In another study, genotype-phenotype correlation between XPC polymorphism and DRC of UVinduced damage was observed (Qiao et al., 2002) . In a Korean study of the XPG His1104Asp polymorphism, Jeon et al. (2003) found that Asp/Asp genotype was more frequent in the controls (28.9%) than in the cases (18.7%), and thus was associated with a significantly decreased lung cancer risk (adjusted OR ¼ 0.54, 95% CI: 0.37-0.80) compared to the referent His/His and His/ Asp genotype combination BER genes: Among the genes involved in BER, most of them are polymorphic (Table 2) . Several polymorphisms have been studied in tobacco-related cancers.
XRCC1 plays an important role in BER. Several polymorphisms have been identified, including Arg194Trp, Arg280His, and Arg399Gln. The association of the Arg399Gln polymorphism of XRCC1 with lung cancer has been inconsistent across studies. Park et al. (2002a) found that the presence of at least one Gln allele was associated with an increased risk of squamous cell carcinoma (OR ¼ 1.77, 95% CI: 1.06-2.93). Similarly, Divine et al. (2001) reported a significant association between the Gln/Gln homozygous variant genotype and adenocarcinoma risk. In the largest study with 1091 
Genetic susceptibility to tobacco-related cancer X Wu et al cases and 1240 controls, the XRCC1 Arg399Gln polymorphism had only a borderline association with lung cancer risk (OR ¼ 1.3, 95% CI: 1.0-1.8; Gln/Gln versus Arg/Arg) . This risk was significantly higher among younger subjects. Among nonsmokers and light smokers, the Gln/Gln genotype was a risk factor for lung cancer, but among heavy smokers it was protective. However, a couple of other studies reported no significant associations between the Arg399Gln polymorphism and lung cancer risk (David-Beabes and Ratnasinghe et al., 2001) . In one study, XRCC1 Arg280His variant allele was found to be associated with increased lung cancer risk (OR ¼ 1.8, 95% CI: 1.0-3.4) (Ratnasinghe et al., 2001) . Wang et al. (2003e) correlated mutagen-induced in vitro chromosomal damage, as assessed by the mutagen-sensitivity assay, with the XRCC1 genotypes in 524 healthy subjects, and their results suggested that the XRCC1 polymorphisms had a functional significance. Duell et al. (2000) examined human blood mononuclear cells of healthy subjects for DNA damage and found that damage as measured by both DNA adducts and sister chromatid exchange were increased among carriers of the XRCC1 399Gln allele. Matullo et al. (2001b) found similar results among nonsmokers only. The product of the OGG1 gene catalyses the excision of a modified base, 8-oxoguanine, which may be formed by exposure to reactive oxygen species. Reduced ability to excise 8-oxoguanine may lead to an accumulation of oxidation-induced mutations. Association of a common Ser326Cys polymorphism in OGG1 with cancer was assessed in several epidemiological studies, and fairly consistent increased risks were observed (Goode et al., 2002) . The largest study was a United States populationbased multiethnic study of lung cancer that identified a significantly increased risk associated with the Cys/Cys genotype (Cys/Cys versus Ser/Ser: OR ¼ 2.1; 95% CI: 1.2-3.7) . A smaller, Japanese hospital-based lung cancer study supported these results (Sugimura et al., 1999) . A third lung cancer study also suggested an increased risk when comparing the two homozygote groups (OR ¼ 2.2; 95% CI: 0.4-11.8) . An increased risk associated with the Cys/Cys genotype was also seen in analyses of esophageal cancer (OR ¼ 1.9; 95% CI: 1.3-2.6) . DSB repair genes: Numerous genes are involved in the repair of DNA double-strand breaks and most of them are polymorphic (Table 2) . However, only a few have been studied in tobacco-related cancers, such as XRCC3. XRCC3 is involved in the HR pathway of DNA DSB repair. The largest analysis of Thr241Met was a United States lung cancer study (331 cases, 667 controls) that found no association after adjustment for ethnicity, age, sex, and smoking status . This was consistent with a smaller study of non-small-cell lung cancer that also found no association after adjustment for age and smoking (Butkiewicz et al., 2001) . In another lung cancer study carried out by Wang et al., no significant association between the XRCC3 variant allele polymorphism and lung cancer risk was noted. However, a significantly increased risk for lung cancer (OR ¼ 5.20; 95% CI: 1.59-17.03) was evident in heavy smokers with the variant T allele genotypes (Wang et al., 2003d) . Furthermore, a joint effect of the T allele and heavy smoking was observed (OR ¼ 37.31; 95% CI: 11.43-121.72). A statistically significant increased risk of bladder cancer was seen among individuals with one or two copies of the rare allele in a small Italian study (TM/MM versus TT, ageadjusted OR ¼ 2.8; 95% CI: 1.3-6.0). In addition, interactions with the NAT-2 genotype were suggested, such that the XRCC3 association was statistically significant only among those with NAT-2 slow genotype (TM/MM versus TT, OR ¼ 3.4; 95% CI: 1.5-7.9) (Matullo et al., 2001a) .
Phenotypic assays Although phenotypic assays are typically laborious, time-consuming, and require highly trained technicians, they can measure the efficiency of the multiple steps of DNA repair. The ability to test the whole pathway is often needed for population studies. A variety of phenotypic assays can assess genetic instability and DRC in population-based studies, including those that assess DNA adducts, metaphase chromosomal aberrations, micronuclei, sister chromatid exchanges, host cell reactivation, and comet assay .
DNA adducts detection: The effects of smoking are evident by the detection of elevated levels of carcinogen-DNA adducts in many human tissues and of carcinogen-protein adducts in the blood. DNA adducts represent an integrated marker of exposure to carcinogenic compounds, and of the ability of the individual to activate metabolically carcinogens and to repair DNA damage. The level of bulky adducts in whole blood has been shown to correlate with external exposure to PAHs in several studies (Nia et al., 2000) . Adducts were negatively associated with the consumption of fruit and vegetables (Palli et al., 2000; Peluso et al., 2000) , possibly through a stimulation of DNA repair (Hu et al., 1996) . A number of methods have been developed to measure DNA adducts in human (Santella, 1999; Phillips, 2002) .
32 P-postlabeling analysis, in which DNA is digested and the resultant carcinogen-modified nucleotides are radiolabeled enzymatically with [ 32 P]orthophosphate, constitutes a sensitive method in which prior knowledge of structures of the adducts is not required. Another method used to detect DNA adducts in human tissues employs antibodies raised against various carcinogen-modified DNA or nucleotides. Immunohistochemistry allows localization of adducts within a tissue specimen, and measurement of fluorescent staining intensity permits a semiquantitative estimate of adduct levels. Thirdly, fluorescence detection of adducts in DNA, or of products released from DNA by hydrolysis, has been used for such carcinogens that have strong fluorescent properties, for example, PAHs. Fourthly, mass spectrometry has been used for the chemical-specific detection of certain adducts in DNA samples. Finally, electrochemical detection has been used for some smaller DNA lesions, such as 8-oxodeoxyguanosine (8-oxo-dG), which is formed in DNA by oxidative processes.
Significantly elevated levels of DNA adducts were detected in the peripheral lung, bronchial epithelium, or bronchioalveolar lavage cells of the smokers in most of the studies. Some studies have found a linear correlation between adduct levels and daily or lifetime consumption of cigarettes (Phillips et al., 1988 (Phillips et al., , 1990 Dunn et al., 1991) . Similar linear relationship was also found in bladder cancer biopsies. Immunohistochemistry analysis of human bladder biopsies with an antibody specific to 4-aminobiphenyl (4-ABP)-DNA adducts detected a correlation with staining levels and smoking history (Curigliano et al., 1996) . Adduct levels were significantly higher in current smokers (n ¼ 24) than in nonsmokers (n ¼ 22) (Po0.0001). There was also a linear relationship between mean levels of relative adduct staining and numbers of cigarettes smoked per day. In a lung cancer study, lung cancer patients who started smoking at earliest age had highest levels of aromatic DNA adducts and 8-oxo-dG in their lymphocyte DNA. The level of aromatic DNA adducts in lung cancer cases was positively correlated with bleomycin-induced chromatid breaks (P ¼ 0.011) (Vulimiri et al., 2000) . In a metaanalysis including a total of 691 cancer patients and 632 control subjects from five lung cancer studies, one oral cancer study, and one bladder cancer study, cases who were current smokers had 83% higher levels of adducts than controls who were current smokers (95% CI: 0.44-1.22) . It suggests that current smokers with high levels of DNA adducts have an increased risk of lung and bladder cancers.
Mutagen-sensitivity assay: Hsu et al. hypothesized that genetic susceptibility to mutagen damage in the general population varies along a continuum, with recognized chromosome fragility syndromes such as Fanconi's anemia and ataxia-telangiectasia being the most extreme (Hsu, 1987; Hsu et al., 1989) . They further reasoned that genetic damage in response to environmental exposures would accumulate more quickly in people with an inherited susceptibility to DNA damage than in other similarly exposed people, and those with the inherited susceptibility might therefore be at a higher risk for cancer. The mutagen-sensitivity assay was therefore developed. Mutagen sensitivity is an in vitro short-term lymphocyte culture assay that gauges host susceptibility by measuring induced chromatid breaks following exposure to an array of mutagens. A series of studies has indicated that mutagen sensitivity is a promising environmental-related cancer risk predictor (Hagmar et al., 1994; Bonassi et al., 1995) . This assay has been successfully expanded by replacing the initial test mutagen bleomycin with 4-nitroquinoline-1-oxide (an UV mimetic agent), g-radiation, and BPDE to measure risk of different cancers (Miller et al., 1998; Wu et al., 1998b; Zhao et al., 2001) . By using a mutagen to induce a specific type of DNA damage, detailed information can be acquired about host susceptibility with regard to a given DNA repair pathway. For example, g-radiation is capable of inducing single-and double-stranded breaks and initiating BER and/or DSB repair pathways. In contrast, BPDE can form covalent adducts when it interacts with DNA, which are repaired by the NER pathway.
In a parallel study of in vitro sensitivity to BPDE and bleomycin in lung cancer and controls, Wu et al. found that lung cancer patients exhibited both higher BPDE and bleomycin induced chromosome breaks than controls. BPDE sensitivity was significantly associated with lung cancer with an OR of 7.26, compared with an OR of 4.56 for bleomycin sensitivity. There was also a doseresponse correlation between the quartiles of BPDEinduced breaks and lung carcinoma risk, with ORs of 2.39, 3.12, and 15.03. A similar dose-response also exists for bleomycin sensitivity. It is worth noting that individuals who were sensitive to both BPDE and bleomycin had a significantly increased OR of 38.36 (Wu et al., 1998b) . In another case-control study in head and neck cancer, case subjects had more BPDE induced breaks than controls (0.7770.38 versus 0.4970.25; Po0.001). In the subsequent quartile analysis, subjects in the highest quartile of chromatid breaks had an approximately 20-fold increased risk of cancer compared with those in the lowest quartile after adjustment for age, sex, ethnicity, and smoking status. The association between BPDE sensitivity and cancer risk was elevated in former smokers and younger patients. In addition, subjects with sensitivity to both BPDE and bleomycin were at a 19.2-fold increased risk of cancer compared with those who were not sensitive to either agent (Wu et al., 1998c) . In recently updated data on 612 lung cancer cases and 557 controls, the mean for bleomycin-induced breaks was significantly higher in lung cancer cases than controls (0.7870.4 versus 0.6270.33; Po0.001). Higher numbers of induced breaks were associated with elevated risk with an OR of 1.89 (95% CI: 1.5-2.4). The risk was elevated in heavy smokers and current smokers (unpublished data).
Comet assay: The concept that inherited (or latent) genetic instability can be unmasked by mutagen challenge and phenotypically measured has been incorporated into other simpler, rapid, and less expensive assays, such as comet assay. The comet assay, which is also called the single-cell gel electrophoresis assay or microgel electrophoresis assay, is a sensitive and rapid method for detecting DNA single-and double-stranded breaks or the DRC in individual cells (Rojas et al., 1999; Tice et al., 2000) . A particular advantage of the assay is that it only requires a relatively small number of cells and has a potential to be high throughput. A further advantage of the comet assay is that it uses image analysis, which reduces the potential for observer bias, and permits densitometric as well as geometric measurements. Schabath et al. used mutagen-challenged comet assay to measure baseline and BPDE-and g-radiationinduced DNA damage in individual PBLs from bladder cancer patients and controls. Baseline levels of DNA damage were statistically significantly higher in the case patients than in control subjects, as were g-radiationand BPDE-induced DNA damage. An increased risk of bladder cancer was statistically significantly associated with DNA damage at baseline (OR ¼ 1.84; 95% CI: 1.07-3.15) and after g-radiation (OR ¼ 1.81; 95% CI: 1.04-3.14) but not after BPDE treatment (OR ¼ 1.69; 95% CI: 0.98-2.93). These data encourage the use of the comet assay in molecular epidemiologic research (Schabath et al., 2003) .
Host cell reactivation assay: Host cell reactivation is another commonly used phenotypic assay to measure DNA repair and damage. In the assay, lymphocytes are transfected with damaged nonreplicating recombinant plasmid harboring a reporter gene. To study tobaccorelated cancers, benzo(a)pyrene is the choice of the challenging mutagen. Activated benzo(a)pyrene, BPDE, can irreversibly damage plasmid DNA by covalent binding or oxidation. The transcription of the reporter gene is completely blocked by BPDE DNA adducts. As even a single unrepaired DNA adduct can effectively block reporter gene transcription, any measurable reporter activity will reflect the ability of the transfected cells to remove BPDE-induced adducts from the plasmids. Using host cell reactivation assay, Wei et al. (2000) found that lung cancer patients had a lower DRC than control subjects (Po0.001), and that reduced DRC was associated with increased risk of lung cancer in a dose-dependent manner (OR ¼ 1.8, 95% CI: 1.1-3.1; OR ¼ 2.0, 95% CI: 1.2-3.4; and OR ¼ 4.3, 95% CI: 2.6-7.2 for the second, third, and fourth quartiles, respectively) (P-value for trend o0.001). Wu et al. developed a novel assay using the luciferase (luc) reporter gene in a host-cell reactivation assay to measure DRC for 4-ABPinduced DNA damage. 4-ABP is a well-studied aromatic amine and a known bladder carcinogen. Bladder cancer cases exhibited poor DRC as compared to healthy controls (13.0 versus 14.4%; P ¼ 0.006). Furthermore, individuals with poor DRC was associated with 3.42-fold increased risk of bladder cancer (95% CI: 1.07-10.91) (unpublished data).
Cell-cycle checkpoint
Signaling pathways monitor the successful completion of upstream events prior to proceeding to the next phase during key transitions in the eukaryotic cell cycle. These regulatory pathways are commonly referred to as cellcycle checkpoints, which are generally at the G 1 /S and G 2 checkpoints. Cells can arrest at cell-cycle checkpoints temporarily to allow for: (i) cellular damage to be repaired; (ii) the dissipation of an exogenous cellular stress signal; or (iii) availability of essential growth factors, hormones, or nutrients (Laiho and Latonen, 2003) . Checkpoint signaling may also result in the activation of pathways leading to apoptosis if cellular damage cannot be properly repaired. Defects in cellcycle checkpoints can result in gene mutations, chromosome damage, and aneuploidy, all of which can contribute to tumorigenesis. Somatic mutations in critical cell-cycle control genes, such as p53 and p21, are directly linked to suboptimal cell-cycle checkpoints and consequently result in chromosomal aberrations, genomic instability, and elevated cancer risk. Therefore, individuals with constitutive defects in cell-cycle checkpoint might be more susceptible to mutagens and have increased cancer risk.
Genetic polymorphisms in cell-cycle-related genes One source of the cell-cycle checkpoint variation might come from genetic polymorphisms in cell-cycle control genes. In SNP500 Cancer Database, 27 cell-cycle-related genes are reported as polymorphic, including genes controlling both the G 1 /S and G 2 checkpoint. However, only a few have been studied in tobacco-related cancers, including CCND1, and p53 and p21, among others.
CCND1: CCND1 is an important positive regulator of the G 1 /S phase. The overexpression of CCND1 is frequently observed in tobacco-related cancers. Three polymorphisms have been reported for this gene in the SNP500 Cancer Database. One of these polymorphisms is a common A/G substitution at nucleotide 870 in the conserved splice donor region of exon 4 of the gene, which causes two different mRNA transcripts (a and b). Both transcripts are present simultaneously in a variety of normal tissues as well as cancer cells (Betticher et al., 1995) . The association between the CCND1 genotype and cancer risk has been studied in several tobaccorelated cancers, including lung cancer, squamous cell carcinoma of the head and neck, squamous cell carcinoma of the oral/pharyngeal cavity, esophageal squamous cell carcinoma, and bladder cancer (Matthias et al., 1998 (Matthias et al., , 1999 Holley et al., 2001; Zheng et al., 2001; Wang et al., 2002a; Cortessis et al., 2003; Qiuling et al., 2003; Yu et al., 2003) . However, the results are not consistent. For example, Qiuling et al. (2003) reported that the CCND1 AA genotype was associated with a significantly increased risk (OR ¼ 1.87, 95% CI: 1.01-3.45) for lung cancer compared to GG genotype, which was even higher in younger individuals and males. A similar finding was reported in head and neck cancer (Zheng et al., 2001 ). In addition, Wang et al. (2002a) also reported that AA genotype was associated with a significantly higher risk of transitional cell carcinoma of bladder compared with the AG þ GG genotypes with adjusted OR of 1.76 (95% CI: 1.09-2.84). However, Cortessis et al. (2003) did not find a significantly increased risk for the AA genotype in bladder cancer (AA versus GG: OR ¼ 0.90, 95% CI: 0.60-1.33). Similarly, Yu et al. (2003) did not find any significant association between the AA genotype and risk of esophageal squamous cell carcinoma.
p53: The p53 gene is one of the most commonly mutated genes in all types of human cancer. Analysis of somatic tissue from many human cancers has shown that the wild-type p53 allele is frequently lost and a mutant allele retained, providing a growth advantage for malignant cells (Vogelstein and Kinzler, 1992; Harris, 1993; Jensen and Page, 1993) . The mutation of the p53 gene can damage its DNA-binding properties and impair cell-cycle control and cell proliferation (Roy et al., 1994) . Of 14 polymorphisms in the p53 gene, three have been widely studied, including a G to C polymorphism at codon 72 (proline/arginine), a 16bp insertion (in intron 3), and a G to A transition (in Genetic susceptibility to tobacco-related cancer X Wu et al intron 6). The association between p53 polymorphisms and tobacco-related cancer risk is highlighted in several lung cancer studies. In a case-control study with 635 pairs of lung cancer patients and healthy controls, Wu et al. found that variant alleles of p53 exon 4, intron 3, and intron 6 were associated with increased lung cancer risk. Similarly, the variant haplotypes were also associated with an increased risk for lung cancer . In a recent meta-analysis of p53 polymorphisms and lung cancer risk, including 16 casecontrol studies, Matakidou et al. (2003) concluded that individuals with p53 exon 4 Pro/Pro genotypes had a 1.18-fold increased lung cancer risk (95% CI: 0.99-1.41). Similar association was observed for p53 introns 3 and 6 polymorphisms. There were a few other studies addressing the role of p53 polymorphisms in other tobacco-related cancers. However, the associations were not consistent Mabrouk et al., 2003) . p21: The association of p21 codon 31 (Ser31Arg) polymorphism with cancer risk has been examined in three lung cancer studies. However, the results are not consistent. Sjalander et al. (1996) found an increased frequency of the variant allele (Arg) in lung cancer patients (Po0.004). However other studies did not observe a similar difference (Shih et al., 2000; Su et al., 2003) . In one bladder cancer study, the variant allele (Arg) was associated with increased risk of bladder cancer, especially invasive bladder cancer (Chen et al., 2002) .
Phenotypic assay Variation of cell-cycle checkpoint can also be assessed by phenotypic assay. Similar to DNA repair, cell-cycle checkpoint is a multigenic and multistep process. Therefore, the ability to test the entire pathway is often needed for population studies.
Cell-cycle arrest assay: When cells are exposed to carcinogens that either delay replication or damage DNA directly, normal wild-type cells delay cell-cycle progression in response to such agents, whereas checkpoint mutants fail to undergo a delay. Therefore, carcinogen-induced cell-cycle delay will be a functional index of cell-cycle checkpoint. Using g-radiation as a challenging mutagen in lymphoblastoid cell lines, Zhao et al. (2001) found that the mean G2 delay was statistically significantly higher in controls than in lung cancer cases (22.50 versus 14.71%, Po0.01). Applying the same assay in the peripheral blood lymphocytes, we found that the medians of the g-radiation-induced accumulations of cells in the S and G 2 phases were significantly lower in the lung cancer patients than in the control subjects. Shorter durations of the S and G 2 phases resulted in an increased risk of lung cancer with ORs of 4.48 (95% CI: 2.67-7.51) and 2.04 (95% CI: 1.24-3.38), respectively (unpublished data). Both studies indicate that cell-cycle checkpoint disruption is a risk factor for lung cancer.
Apoptosis
The activation of the apoptosis pathways is a vital mechanism conferring protection from tumorigenesis following genotoxic attack. Defects in apoptosis signaling may contribute to cancer development and progression. The activation of apoptosis signaling following genotoxic attack has been shown to lead to the activation of the mitochondrial (intrinsic) pathway of apoptosis. In addition, signaling through the death receptor (DR) (extrinsic) pathways contributes to sensitivity of cells towards cytotoxic treatment. Both pathways converge at the level of caspase activation, leading to cell death (Debatin, 2004) . Although apoptosis is evolutionarily conserved, there may be interindividual variation in apoptotic capacity in general population. Individuals with suboptimal apoptosis capacity might be more susceptible to carcinogeninduced damage than those with normal apoptotic capacity.
Genetic polymorphisms in apoptosis pathway A large number of proteins are involved in the apoptosis pathway, such as cytochrome c, apoptosis-inducing factor, Smac, endonuclease G, caspase-2 and -9 in mitochondrial pathway, TNF receptor superfamily, FADD and caspase-8 in DR pathway, and Bcl-2 family, among others. Genetic polymorphisms in apoptosis pathway genes might contribute to the variation of apoptotic capacity. According to SNP500 Cancer Database, 30 apoptosis-related genes are found to be polymorphic, including genes from both mitochondrial and DR pathways. However, only a few polymorphisms have been studied in tobacco-related cancers, including DR4, p53 and Fas, etc.
DR4: Allelic loss of chromosome 8p21-22 occurs frequently in lung and head and neck squamous cell cancer. The tumor necrosis factor-related apoptosisinducing ligand (TRAIL) receptors, including proapoptotic DR4 and KILLER/DR5, are located on 8p21-22. TRAIL receptors are candidate tumor suppressor genes (TSGs), because their inactivation would result in deficient apoptotic signaling. In DR4 exon 4, a C-G polymorphism at amino acid 626 is located immediately 3 0 to one of the main receptor ligand interface regions, which results in a threonine-arginine change (Fisher et al., 2001) . Hazra et al. (2003) found that the DR4 exon 4 G/G genotype was associated with an overall 42% decreased risk of bladder cancer in Caucasians. This protective effect was more apparent in younger individuals, women and light smokers. In another lung cancer study, the frequency of DR4 variant allele was statistically significantly different between lung cancer cases and controls (P ¼ 0.023) (Fisher et al., 2001) . These data suggest that the DR4 polymorphism is associated with environmental exposure and cancer risk, possibly through the modulation of the capacity of the receptor ligand complex to engage the apoptotic pathway. Fas: The tumor necrosis factor/nerve growth factor receptor superfamily triggers apoptosis, and Fas (also known as Apo-1/CD95) is one of the most important and well-characterized genes involved in apoptosis. The Fas gene, which codes cell-surface receptors involved in Genetic susceptibility to tobacco-related cancer X Wu et al cell-death signaling, is highly polymorphic, particularly in its promoter region. One of these polymorphisms is an A-G base change at nucleotide À670 in the enhancer region. This variant abolishes the binding site for the nuclear transcription element GAS (interferon-gactivated sequence) and alters the expression of the Fas gene (Huang et al., 1997) . The Fas A-670G polymorphism was not found to be an independent risk factor for lung cancer. However, the adjusted ORs for lung cancer risk associated with lower apoptotic capacity were 4.00 (95% CI: 1.48-10.80) among those with the Fas G variant allele and 0.97 (95% CI: 0.18-5.30) among those without the Fas G variant allele (Wang et al., 2003c) .
Phenotypic assay Several methods can be applied to measure the apoptosis, including the TUNEL assay, and DNA fragmentation. In lymphoblastoid cell lines from both lung cancer patients and healthy controls, Zhao et al. (2001) found that the mean apoptosis capacity was statistically significantly higher in controls than in lung cancer cases (20.4 vs 14.3%, Po0.05) after exposure to g-radiation. In another study using a BPDE challenge, Wang et al. (2003c) observed a significantly lower apoptosis capacity in lung cancer patients (155.2%) than in the controls (216.6%) (Po0.05), and low apoptosis capacity was associated with increased lung cancer risk with OR of 2.69 (95% CI: 1.18-6.15).
Several genetic polymorphisms in apoptosis-regulating genes have been linked to modified apoptosis. Biros et al. (2002) found that lung cancer patients with one copy of p53 exon 4 variant allele had a lower content of apoptotic white blood cells when compared to patients without exon 4 variant allele (Po0.001). A similar trend was observed for p53 intron 6 variant allele (Po0.05). In another lung cancer study, Wu et al. (2002) found that lymphoblastoid cell lines with all p53 wild-type alleles at the three loci (exon 4, intron 3, and 6) had statistically significantly higher apoptotic indices (13.66%) than cell lines with at least one variant allele at all three loci (3.50%). In addition, clinical response following cisplatin-based chemo-radiotherapy for advanced head and neck cancer is modulated by p53 exon 4 polymorphism (Pro72Arg) as individuals with Arg allele have lower response rates than those with the Pro allele. This is due to the inhibition p73 by p53 Arg allele. Inhibition of p73 leads to the abrogation of apoptosis and cytotoxicity induced by cisplatin. Therefore, polymorphisms in p53 may influence individual responsiveness to cancer therapy (Bergamaschi et al., 2003) .
Telomere and telomerase
Telomeres are TTAGGG repeat complexes bound by specialized nucleoproteins at the ends of chromosomes in all eukaryotic cells (McEachern et al., 2000; Blackburn, 2001 ). By capping the ends of chromosomes, telomeres prevent nucleolytic degradation, end-to-end fusion, irregular recombination, and other events that are normally lethal to a cell. There are at least two ways of disrupting normal telomere function: (1) progressive loss of telomere sequences due to the end-replication problem and the absence of telomerase in most normal somatic cells; and (2) disruption of higher-order telomere structures due to the defects in various telomere-binding proteins. Mutations in these telomere-binding proteins, such as TRF1 and TRF2, have been shown to disrupt telomere structure and cause chromosome instability in the absence of significant telomere shortening (de Lange, 2002) . Telomere dysfunction constitutes a molecular mechanism of genetic instability (Wong et al., 2000; Hackett et al., 2001; McEachern and Iyer, 2001; Smogorzewska et al., 2002; Chan and Blackburn, 2003) . Moreover, the combination of telomere dysfunction and p53 deficiency has been shown to accelerate tumorigenesis in vivo (Chin et al., 1999; Gisselsson et al., 2001) . Although telomerase is reactivated in most human cancers, telomere shortening and dysfunction might impair chromosomal stability early in carcinogenesis and, consequently, drive the initial carcinogenic process.
In addition to the role of telomere in the protection of chromosome ends, telomeres may also be involved in the process of chromosomal repair, as shown by the recruitment or de novo synthesis of telomere repeats at double-stranded breaks and by the ability of yeast telomeres to serve as repositories of essential components of the DNA repair machinery, particularly those involved in nonhomologous end joining (Haber, 1999; Martin et al., 1999) .
Since telomere dysfunction leads to genetic instability, individuals with telomere dysfunction may be more likely to exhibit genetic instability and therefore be at a higher risk for developing cancer. Wu et al. have developed an improved quantitative Laser Scanning Cytometer-based approach, Q-FISH LSC , for evaluating telomere length distribution in individual cells based on in situ hybridization using a fluorescein-labeled PNA (CCCTAA) 3 probe and DNA staining with propidium iodide. This protocol is simple and rapid with high reproducibility, giving results within 3-4 h (Wu et al., 2003a) . Using either Southern blotting or Q-FISH LSC , Wu et al. investigated whether telomere dysfunction, as assessed by telomere length, was associated with the risk of four smoking-related cancers -head and neck, bladder, lung, and renal cell cancer -in four ongoing case-control studies. Telomeres were statistically significantly shorter in patients with all four smokingrelated cancers than in control subjects (Po0.001). When subjects were categorized into telomere length quartiles defined by the distribution in control subjects, the following inverse relationship between telomere length and cancer risk was observed: adjusted OR for decreasing quartiles ¼ 0.84 (95% CI: 0.36-1.97), 1.77 (95% CI: 0.72-4.36), and 5.11 (95% CI: 1.90-13.77). In stratified analysis, a suggestive greater-than-additive interaction between smoking status and telomere length was observed. Telomere length was statistically significantly and inversely associated with baseline and mutagen-induced genetic instability. These data provide the first epidemiologic evidence that shortened telomeres increase cancer risk. The data also lend support to the hypothesis that environmental carcinogens may operate through the telomere to increase genetic instability and cancer susceptibility.
Microenvironmental factors
The interactions between neoplastic cells and their surrounding microenvironment have been well documented. Many studies support the concept that carcinogenesis is a multicellular and multistage process in which the destruction of the microenvironment is required for the conversion of normal tissue to tumor.
Matrix metalloproteinases MMPs can degrade a range of extracellular matrix and nonmatrix proteins, and play an essential role in tissue remodeling and repairing associated with development and inflammation (Joos et al., 2002) . MMPs comprise a structurally and functionally related family of more than 20 proteolytic enzymes, which include collegenases, gelatinases, matrilysins, and stromelysins. Substrates of these enzymes are collagens, aggrecan, decorin, fibronectin, elastin, and casein, among others. Both TIMPs (tissue inhibitors of metalloproteinases) and MMPs are secreted by stromal and tumor cells, and it has been shown that an imbalance between MMPs and their naturally occurring inhibitors may cause an excess of extracellular matrix destruction. This excessive matrix destruction has been linked to the occurrence and progression of various diseases, including cancer invasion, recurrence, and metastasis (Hojilla et al., 2003) .
SNPs in the promoter regions of selected MMP genes, such as MMP 1, 2, 3, 7, 9, and 12, have been an area of intensive study in recent years. The list of promoter polymorphisms of MMP gene is in Table 3 . Promoter polymorphisms leading to gene over-or under-expression can change the vital TIMP/MMP balance.
MMP1: Among the MMPs, MMP1 is the most highly expressed interstitial collagenase and degrades fibrillar collagens, the most abundant proteins in the human body. The overexpression of MMP1 is shown in tumor tissues and has been linked to tumor invasion and metastasis, as well as poor prognosis in colorectal and esophageal cancers (Murray et al., 1996 (Murray et al., , 1998 . Zhu et al. (2001) studied a promoter insertion in MMP1 and found that the 2G/2G genotype was associated with a 1.76-fold increased lung cancer risk (95% CI: 1.29-2.39). The risk was even higher in current smokers and heavy smokers. This 1G/2G polymorphic site is found in a core recognition sequence of the binding sites for transcription factors that consequently modifies the level of its expression. Promoters containing the 2G allele display significantly higher transcriptional activity than the 1G promoters. Hirata et al. (2003) observed a higher frequency of 2G alleles in renal cell carcinoma patients than in healthy controls.
MMP2: MMP2 is a well-studied gelatinase whose substrates include gelatins, collagens, and fibronectin. MMP-2 has been shown to play an important role in cancer progression. In esophageal carcinomas, high MMP-2 levels were associated with tumor invasion (Shima et al., 1992) . In bladder cancer, higher MMP-2 expression was associated with poorer prognosis (Kanayama et al., 1998) . A C/T SNP in MMP2 promoter region (C/T À1306) results in lower promoter activity and is associated with reduced lung and gastric cancer risks (Yu et al., 2002; Miao et al., 2003) .
MMP3: MMP3 is a stromelysin whose substrates include collagens, gelatin, aggrecan, fibronectin, laminin, and casein. An MMP3 insertion at À1612, which lead to MMP3 overexpression, was shown to be associated with colorectal and breast cancer risks (Ghilardi et al., 2002; Hinoda et al., 2002) .
MMP9: MMP9 is a gelatinase and its function is similar to that of MMP2. The role of MMP9 in cancer has been explored extensively. MMP9 was overexpressed in several types of cancer. A C/T SNP at À1562 has been shown to lead to gene overexpression (Minematsu et al., 2001) .
MMP12: MMP12 is a metalloelastase required for macrophage-mediated extracellular matrix proteolysis and tissue invasion. Its expression has been strongly associated with histologic aggressiveness and metastasis in cancer. An A/G transition at À82 in MMP12 promoter region leads to lower promoter activity, and hence lower MMP12 expression.
Inflammation Inflammation is a complex cellular response to a variety of endogenous and environmental stimuli, including heat, trauma, and viral/bacterial infections, in which a multifactorial network of chemical signals initiate and maintain a host response designed to heal the afflicted tissue (Ballaz and Mulshine, 2003) . Normal inflammation, for example, inflammation associated with wound healing, is usually self-limiting, because the production of anti-inflammatory cytokines follows the proinflammatory cytokines closely. In contrast, chronic inflammation deregulates cellular homeostasis and can drive carcinogenesis. Many cancers arise from sites of inflammation. It is estimated that chronic infection and associated inflammation contribute to about one in four of all cancer cases worldwide. Examples of chronic inflammation and cancer occurrence include bronchitis/emphysema and lung cancer (Mayne et al., 1999; Malkinson et al., 2000) , schistosomiasis and bladder cancer (Badawi et al., 1995) , asbestos fiber inhalation and mesothelioma (Manning et al., 2002) , chronic esophagitis and esophageal cancer, (McCann, 1999) , Helicobacter pylori infection and gastric cancer (Williams and Pounder, 1999) .
Immunomodulatory genes can modify the balance between proinflammatory and anti-inflammatory genes, (Tsai et al., 2001; Landi et al., 2003; Zambon et al., 2004) . IL6-174 G4C is an SNP affecting the transcription of the gene and altering the released IL-6 level (Fishman et al., 1998) . PPARG, which encodes a nuclear receptor transcription factor, has a polymorphism in the coding region (34C4G) that results in the amino-acid change (Pro12Ala). The G34 (Ala12) allele is associated with reduced risk of type II diabetes (Fajas et al., 1997) , improved insulin sensitivity (Altshuler et al., 2000) , and lower risk of renal cell carcinoma . In CRC, the IL6 -174 C variant allele is associated with increased risk (1.53, 95% CI: 1.12-2.09) and the PPARG Ala12 variant allele is associated with reduced risk (0.56, 95% CI: 0.37-0.85) (Landi et al., 2003) . In a renal cell carcinoma study, PPARG Ala12 variant allele was under-represented in renal cell carcinoma patients compared to controls (3.75 versus 12.1%, Po0.04) . Using a bladder cancer case-control study, we observed that the variant IL6 genotype is associated with increased risk of bladder cancer (1.52, 95% CI, 1.02-2.28). Furthermore, individuals with both the variant genotypes for both IL6 (C/ C) and PPARG (C/G þ G/G) had an increased risk with an OR of 2.76 (95% CI: 1.42-5.35) (unpublished data).
Growth factors
It has been hypothesized that cells with accelerated rates of division and proliferation are predisposed to the development of cancer. Insulin-like growth factor (IGF-I) is an important mitogen required for both normal and cancerous cell progression through the cell cycle. IGF-Imediated activation of its receptor stimulates the tyrosine kinase pathway and initiates Ras and PI3 kinase-related signal transduction pathways (Aaronson, 1991; LeRoith et al., 1995) . IGFs also suppress apoptosis by stimulating the expression of Bcl-2 proteins and suppressing the expression of Bax, thereby blocking the initiation of the apoptotic pathway (Dunn et al., 1997) . The effects of IGF-I are regulated through its interactions with IGF-I receptor and IGF-binding proteins. More than 90% of circulating IGFs are complexed with IGF-binding protein-3 (Nickerson et al., 1997) . IGF-binding proteins can inhibit the mitogenic action of IGFs by blocking the binding of IGFs to their receptor. Under certain circumstances, IGF-binding proteins can also enhance IGF action by protecting IGFs from degradation (De Mellow and Baxter, 1988) . Twin studies have indicated that approximately 38% of interindividual variations in circulating IGF-I levels and 50% of intraindividual variations in circulating IGFBP-3 levels are genetically determined (Harrela et al., 1996; Hong et al., 1996) . Rotwein et al., identified a highly polymorphic cytosine-adenosine dinucleotide repeat (CA) n 1 kb upstream from the transcription start site of IGF-I (Rotwein et al., 1986) . This polymorphism is located in the promoter region of IGF-I, which was shown in rats to contain regulatory elements that may alter transcription. The correlation between IGF-I (CA) n repeat polymorphism and serum/plasma levels of IGF-I has been explored in several studies (Rosen et al., 1998; Jernstrom et al., 2001; Vaessen et al., 2001) . However, the results are not consistent. Five polymorphic loci in IGFBP-3 were detected and the genotype at one of these loci (À202) was found to be associated with age-adjusted circulating IGFBP-3 concentration ). This locus is close to elements believed to regulate the basal promoter activity of IGFBP-3. Studies showed that mean IGFBP-3 levels are highest among individuals with the À202 AA genotype, with a significant stepwise decline in IGFBP-3 levels in the presence of one or two copies of the C allele. The relationship between IGFBP-3 polymorphism and cancer risk has been investigated in only one CRC study which did not find a significant association .
Epigenetic events
In recent years, there has been an explosion of literature supporting the hypothesis that both abnormal genetic and epigenetic events play an important role in tumorigenesis. Epigenetic refers to a heritable change in gene expression without alterations in the primary DNA sequence of a gene (Jones and Baylin, 2002; Herman and Baylin, 2003) . Deregulated epigenetic changes, usually represented by abnormal DNA methylation patterns such as global hypomethylation and region-specific hypermethylation, are a hallmark of most cancers, including tobacco-related cancers. The major epigenetic aberration that takes place in cancer development is the inactivation of TSGs through the hypermethylation of CpG islands in their promoter regions. The number of cancer-related genes affected by epigenetic inactivation equals or exceeds the number that are inactivated by mutation (Herman, 1999; Jones and Laird, 1999 ). Knudson's two-hit model proposed that two successive genetic 'hits' are needed to transform a normal cell into a tumor cell, that is, two inactivating 'hits' are required to cause loss of function of TSGs. The functional significance of TSG hypermethylation is appreciated by several studies showing that TSG hypermethylation acts as the second inactivating hit of TSG following the first-hit gene mutation (Myohanen et al., 1998; Grady et al., 2000) .
Genetic polymorphisms in methylation-related genes Although the precise mechanisms underlying alterations of methylation patterns are far from complete, the key players in CpG island methylation and resulting transcription silencing are: DNA methylatransferase (DNMTs), which is responsible for de novo synthesis and maintenance of methylation, and methyl-binding proteins, which bind to methylated DNA and recruit repression complexes containing histone deacetylaces. Given that aberrant promoter methylation plays an important role in tumorigenesis, polymorphisms in methylation-related genes may modify cancer risk by interfering with the normal methylation process. Indeed, Shen et al. (2002) identified a C-T transition at a novel promoter region of DNMT3B gene, which significantly increases the promoter activity. Compared with CC homozygotes, the combined variant genotype (CT þ TT) was associated with a nearly twofold increased risk for lung cancer. Another well-studied polymorphism is the C677T transition in methylenetetrahydrofolate reductase (MTHFR), a key enzyme in folate metabolism, which also plays a major role in the provision of methyl groups for DNA methylation. The C-T transition, which results in an alanine to valine missense mutation and reduces the MTHFR activity, has been studied in several tobacco-related cancers, including lung, esophageal, and bladder cancer. Stolzenberg-Solomon et al. (2003) found that individuals with the MTHFR 677TT genotype had significantly higher combined esophageal cancer risks (RR ¼ 1.45; 95% CI: 1.02-2.05) than those with CC or CT genotypes in a Chinese cohort. In another Chinese study, individuals with the 677TT genotype had a more than sixfold increased risk of developing esophageal cancer (OR ¼ 6.18; 95% CI: 3.32-11.51) compared with those who had the 677CC genotype . Similar association was not observed in two other lung cancer studies and one bladder cancer study (Shen et al., 2001a; Jeng et al., 2003; Sanyal et al., 2004) .
Genetic imprinting Genomic imprinting is a kind of epigenetic event that distinguishes maternal and paternal alleles so that only one specific parental allele is expressed in somatic cells of the offspring (Pfeifer, 2000; Ferguson-Smith and Surani, 2001; Reik and Walter, 2001) . Loss of imprinting (LOI) thus refers to the aberrant expression of both maternal and paternal alleles (or biallelic expression) of the otherwise monoallelic expression of imprinted genes (Feinberg et al., 2002) . The most commonly affected gene by LOI identified to date is IGF-II, which is a growth-promoter gene with paternal expression in normal imprinting. Numerous studies have shown that LOI of IGF-II, which results in the expression of normally silent maternal allele, and thus may lead to the overexpression of IGF-II is a frequent alteration in a variety of inherited and sporadic cancers (Feinberg et al., 2002) . Even more interesting, recent literature suggests that LOI of IGF-II may be an epigenetic trait that is polymorphic in the population, and that individuals with inherited LOI of IGF-II may be predisposed to certain cancers. LOI of IGF-II was found in the tumors and matched normal colonic mucosa of 30% of CRC patients, as compared with 10% of healthy individuals (Cui et al., 1998) . In a pilot study to investigate the utility of LOI as a marker of CRC risk, Cui et al. (2003) evaluated 172 patients at a colonoscopy clinic. LOI was found in peripheral blood lymphocytes of 25 patients. The adjusted odds ratio for LOI was 5.15 for patients with a positive family history, 3.46 for patients with adenomas, and 21.7 for patients with CRC. Woodson et al. (2004) also found that LOI of IGF-II was associated with a fivefold increased risk of adenoma formation in women. On average, IGF-II expression was more than threefold higher among women with LOI of IGF-II than among women with normal imprinting status. These results suggest that LOI of IGF-II may play a role in CRC and may be a valuable predictive marker of an individual's risk for CRC. Whether LOI of IGF-II can be a susceptibility marker for cancers other than CRC is a question that is still being studied.
Genetic variations in clinical outcomes
Inherited markers of genetic susceptibility to cancer have largely been used to predict occurrence of disease rather than disease outcome. The use of inherited genetic markers to evaluate cancer outcome could enhance our ability to identify those persons who are more likely to develop clinically significant cancer and to intervene to reduce morbidity and mortality resulting from cancer. Genetic susceptibility may influence the natural history of disease by acting directly in tumor etiology. For example, inherited genotypes may influence tumor histopathology including the stage or grade of disease, the rate of disease progression, or the propensity for metastasis. Genetic susceptibility may also influence an individual's response to either chemoprevention or the pharmacological treatment of disease. For example, inherited genotypes may influence the bioavailability of a chemopreventive or chemotherapeutic agent, or they may predict the occurrence of toxicities that influence an individual's cumulative timing or dose of exposure.
Pharmacogenetics
It is well recognized that patients can respond in different ways to the same medication. Even though individual differences in drug response can result from the effect of age, sex, disease, or drug interaction, genetic factors influence both the efficacy of a drug, and the extent of an adverse reaction. It is estimated that genetic factors can account for 20-95% of variability in drug disposition and effect (Kalow et al., 1998) . Interindividual variation in response to a drug can be accounted for, at least in part, by polymorphisms in the genes involved in the metabolism of the drug, or polymorphisms in genes encoding drug-metabolizing enzymes, drug transporters, or drug targets. In the area of cancer chemotherapy, inherited genetic variations can be used to predict individual's response to cancer therapy agents. Using the knowledge of these variations to tailor therapy for improved response and reduced toxicity is a major challenge for cancer treatment. It holds a great potential for achieving the goal of genetically guided cancer therapy. DNA repair is a major variation factor of response in several cancer chemotherapeutic agents, including cisplatin, cyclophosphamide, and others, because these agents will cause DNA damage, which accounts for their therapeutic cytotoxic properties. It is generally postulated that individuals that are defective in DRC become more sensitive to cisplatin and cyclophosphamide than those that have normal DRC. Bosken et al. (2002) found that effective host DRC may be associated with poorer survival in patients with non-small-cell lung cancer who are treated with platinum-based chemotherapy. The XPD Lys751Lys genotype, which is related to suboptimal DRC, was observed to be associated with longer median survival in CRC patients treated with oxaliplatin/FU . In another study, a trend toward better response was observed in non-small-cell lung cancer patients with XPD Asp312Asn SNP, although the correlation did not reach statistical significance (Camps et al., 2003) .
Genetic polymorphisms in inflammation genes can also modify individual response to immunotherapy. Bacillus Calmette-Guerin (BCG) treatment is a common immunotherapy treatment for superficial bladder cancer. Its molecular mechanism is related to the stimulation of the immune system, especially the IFNg production. In our study, we found that variation in proinflammatory genes may play a role in the modulation of inflammatory responses that alter the therapeutic effects of BCG therapy. In patients receiving maintenance BCG, the variant IL6 genotype was associated with an increased recurrence risk (unpublished data).
Genetic polymorphisms in natural history of disease
Genetic polymorphisms in carcinogen metabolic genes can predict the natural history of tobacco-related cancers. Sweeney et al. reported that lung cancer subjects with the GSTM1 null genotype had shorter survival, and that the proportion of GSTM1 null subjects surviving at 5 years was 0.20 (95% CI: 0.14-0.27), compared with 0.29 (95% CI: 0.22-0.37) for GSTM1 present subjects. The relative risk of death associated with GSTM1 null genotype, adjusted for stage at diagnosis and histology, was 1.36 (95% CI: 1.04-1.80) (Sweeney et al., 2003) . In another lung cancer study, variant alleles of CYP1A1 and GSTM1 were associated with a variety of clinical outcomes, including histological type, performance status (general condition of patients), and the extent of the primary tumor (Tfactor) and survival (Goto et al., 1996) . In bladder cancer, Inatomi et al. (1999) showed that bladder cancer patients with NAT2 slow genotypes were more likely to have a high-grade tumor (G3) or an advanced stage tumor (pT2-pT4). Also, significant associations between TNF polymorphisms TNF þ 488A and TNFÀ859T and grade of bladder cancer were observed (Marsh et al., 2003) .
Genetic polymorphisms in cell-cycle checkpoint control genes can also predict natural history of tobaccorelated cancers. For p53 Pro72Arg SNP, Wang et al. (1999) reported that lung cancer patients with the Pro/ Pro genotype had a worse prognosis compared with those with Arg/Pro genotypes, especially for patients with squamous cell lung cancer (P ¼ 0.013), male patients (P ¼ 0.028) and those aged 60-69 years (P ¼ 0.052). In patients with early stage lung cancer, patients with Pro/Pro and Arg/Arg genotypes had a tendency for a worse prognosis than those with the Arg/ Pro genotype (P ¼ 0.057). For CCND1 polymorphism, (Betticher et al. (1995) reported that CCND1 variant genotype is associated with shortened event-free survival and a greater risk of local relapse in patient with nonsmall-cell lung cancer. Matthias et al. (1998) reported that the distribution of CCND1 genotypes in squamous cell carcinomaof the head and neck cases with poorly differentiated tumors was significantly different from that in patients with well-/moderately differentiated tumors (P ¼ 0.016). GG genotype was associated with poorly differentiated tumors (G3). In addition, CCND1 GG was associated with reduced disease-free interval in patients with squamaous cell cercinoma of the head and neck (hazard ratio ¼ 2.95; 95% CI: 1.54-5.63). However, in a bladder cancer study, Wang et al. (2002a) reported that the presence of the CCND1 A allele was associated with higher grade ( ¼ grade 3) tumors with a gene dosage effect (P ¼ 0.008). The AA þ AG genotypes tended to be more frequently observed in cases with T1-4 tumors than those with Ta tumors (OR ¼ 1.94, 95% CI: 0.98-3.82).
Pitfalls and perspectives
The above promise of molecular epidemiology notwithstanding, many factors need to be considered before genetic predisposition factors to cancer can be fully incorporated into the validation of a causal association with specific exposures.
SNP prioritization: Given that there are millions of SNPs in the entire human genome, a major difficulty faced by molecular epidemiologists in planning costly population-based genotyping is to target SNPs that are most likely to affect phenotypic functions and ultimately contribute to disease development. One approach to select SNPs is using computational algorithms. These include an evolutionary approach, using sorting intolerant from tolerant (SIFT) and Bayesian phylogenetic analyses, and a structural-based approach known as polymorphism phenotyping (POLYPHEN) for coding SNPs. Coding SNPs are of particular interest because some of them, termed nonsynonymous SNPs (nsSNPs), introduce amino-acid altering polymorphisms into their encoded proteins. Computational algorithms are useful for characterizing high-priority variants because they have the ability to be employed on a scale that is consistent with the large number of variants found in the human genome. Using SIFT, Zhu et al. (2004) found a significant relationship between the detected odds ratios associated with cancer risk and the conservation levels of the SNP-affected amino acids (P ¼ 0.002) for 46 SNPs in 39 different cancer-related genes from 166 molecular epidemiological studies. Another approach to identify functional SNPs is experimental, using in vitro or in vivo assays to look at RNA stability or degradation, protein structure, protein denaturing, protein expression, and tissue specificity. A new method was recently developed with analysis using HaploCHIP to examine SNPs that affect gene regulation in vivo (Knight et al., 2003) . Those SNPs located in the regulatory regions will be constrained to some extent under selective pressure and may be equally important in disease risk estimates. The functional significance of these SNPs cannot be predicted by SIFT and POLYPHEN. The HaploCHIP approach can assess the functional significance of SNPs in the 5 0 -end regulatory regions. The implications of this development are very exciting, but the manner in which this approach can be applied in molecular epidemiology studies is still being explored.
Pathway approach versus candidate gene approach: Despite a growing list of positive associations reported for gene polymorphisms and cancer risk, some of the findings are not consistent (Goode et al., 2002) . The inconsistency might be mediated by conducting large, well-designed studies; however, carcinogenesis is a multifactorial and multistage process that is dependent on a myriad of mechanisms and pathways regulating absorption, metabolic activation and excretion, DNA repair, control of mitotic cycle, hormonal stimulation of cell growth, inflammatory responses, and many other local or distant events that themselves are under genetic control. For this reason, it will be difficult to detect subtle differences in phenotype as the result of a single polymorphism of a single gene in a very complex pathway. It may be necessary to evaluate the functional relevance of SNPs by concurrently genotyping a comprehensive list of SNPs in each pathway to test them globally as genetic risk factors for tobacco-related cancer. Such a selection should be made by carefully considering the putative genetic and epigenetic pathways involved for the relevant agent and organ system. This approach will not only permit us to comprehensively assess the individual contribution of SNPs in each pathway to tobacco-related cancer risk, it will also allow us to assess the joint effect of multiple pathways on cancer risk. Such a pathway-based approach will certainly yield more informative results than studies focusing on one or a few genotypes, by allowing us to evaluate both the relative importance of each gene and the potential interactions between genes.
SNPs versus haplotypes: SNPs are not inherited independently; rather, sets of adjacent SNPs are usually inherited in blocks. The specific pattern of particular SNP alleles in a block is called a haplotype. Recent studies show that most haplotype blocks in the human genome have been transmitted through many generations without recombination. Furthermore, each block has only a few common haplotypes. This means that, although a block may contain many SNPs, it takes only a few SNPs to uniquely identify or 'tag' each of the haplotypes in the block. For these reasons, haplotype information allows fewer SNPs to be genotyped per gene, thereby reducing cost and improving throughput. In appropriate circumstances, haplotypes have the advantage of carrying more information about the genotype-phenotype link than do the underlying SNPs.
For example, haplotypes provide an advantage when the contributing SNPs are not all directly observed. In addition, haplotype analysis has the advantage when there is no additive phenotypic effect of consecutive SNPs. Although haplotypes are superior markers in appropriate circumstance, it is not easy to determine the haplotype. Two approaches are available to measure the haplotype, including molecular haplotyping and computational haplotyping. However, molecular haplotyping is not high-throughput, and computational haplotyping is statistically based and requires that a population rather than an individual be analysed. Therefore, are SNPs or haplotypes better? The answer is, in most cases, that the combination of SNPs and haplotypes will be the most powerful.
Genotypic assays versus phenotypic assays: There are numerous assays to capture the variability in genetic susceptibility and they can be broadly divided into genotypic assays and phenotypic assays, depending on whether they directly probe the genome (DNA sequence for a target gene) or gene expression and cellular activity. Some phenotypic assays measure effects from a combination of genes, some of which are unidentified. Recently, new phenotypic assays have appeared that permit the study of cell-cycle checkpoints, DNA damage/repair (mutagen sensitivity, comet assay, host cell reactivation assay), and detection of DNA adducts, as well as contributions from proteomic technology (Wu et al., 1998b-c; Santella, 1999; Zhao et al., 2001; Schabath et al., 2003) . Although phenotypic assays have the advantage over genotypic assays due to the multigenic and multistep nature of carcinogenesis, genotypic assay is quicker, easier to perform, and more cost-effective. Many questions remain to be answered. For example, are phenotypic assays practical for largescale epidemiology studies? Currently, functional assays that require viable lymphocytes are not suitable for large-scale population-based epidemiological studies of cancer susceptibility. Can genotypic assays replace phenotypic assays? What is the correlation between phenotypic and genotypic assays? Currently, there is little or no knowledge of the functional relevance of many of the DNA repair polymorphisms that are studied.
Biomarker validation: Although molecular epidemiology has been rapidly grown in last decades, few markers have been validated to the point where they can be applicable to risk assessment or clinical outcome prediction. There is a need to develop exposure pathway specific biomarkers and validate them for population studies. Validation studies will need to keep pace with technological progress in assay development. Robust study designs, conservative control of confounding factors, and state-of-the-art laboratory procedures in terms of reproducibility, reliability, inter-and intralaboratory variability, etc., are essential for biomarker validation.
Conclusion remarks: Over the last decade, molecular cancer epidemiology, which helps unveil potential genegene and gene-environment interactions in cancer causation, has come from obscurity to prominence. Considerable progress, as illustrated above, has been made in our understanding of genetic susceptibility factors to tobacco-related cancers. Extensive genetic polymorphism comparisons between cancer patients and controls have provided us with invaluable information, which will facilitate identifying high-risk population of developing cancer. In addition, susceptibility genes may underlie phenotypic changes, such as DNA repair deficiency, telomere dysfunction and chromosomal aberration, which will also assist in predicting cancer risk. However, despite all the information accumulated over the years, there is still a long way to go before we can reach our ultimate goal, that is, a practical risk-assessment model to predict high-risk people for cancer or clinical outcomes, which will have substantial preventive and clinical implications. In the next decade, molecular epidemiologists, empowered by rapid advances in genetic and molecular understanding of cancer, will undoubtedly take on the difficult task and inch close to the ultimate goal.
